Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 640 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ipilimumab Clear all
Completed Phase 2 Interventional Results available

Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer

NCT01804465
View directory record Official record
Conditions
Prostate Cancer
Interventions
SipT Treatment, Ipilimumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
San Francisco, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 28, 2026, 4:02 PM EDT
Withdrawn Phase 1Phase 2 Interventional

CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)

NCT04060407
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
CD24Fc, Ipilimumab, Nivolumab
Drug
Lead sponsor
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 28, 2026, 4:02 PM EDT
Recruiting Early Phase 1 Interventional

Implantable Microdevice In Primary Brain Tumors

NCT04135807
View directory record Official record
Conditions
Grade II Glioma, Grade III Glioma, Grade IV Glioma, Astrocytoma, Oligodendroglioma of Brain, Anaplastic Astrocytoma of Brain, Anaplastic Oligodendroglioma, Glioblastoma
Interventions
Microdevice
Combination Product
Lead sponsor
Oliver Jonas
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 28, 2026, 4:02 PM EDT
Terminated Phase 1Phase 2 Interventional

Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

NCT05220722
View directory record Official record
Conditions
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Interventions
SD-101, Pembrolizumab, Nivolumab, Ipilimumab
Drug · Biological
Lead sponsor
TriSalus Life Sciences, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Aurora, Colorado • New York, New York • Providence, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 28, 2026, 4:02 PM EDT
Suspended Phase 1 Interventional

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

NCT04418167
View directory record Official record
Conditions
Solid Tumors
Interventions
JSI-1187, Dabrafenib
Drug
Lead sponsor
JS InnoPharm, LLC
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 28, 2026, 4:02 PM EDT
Terminated Phase 1 Interventional Results available

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

NCT04840615
View directory record Official record
Conditions
Mesothelioma
Interventions
LMB-100, ipilimumab, Diphenhydramine, Famotidine, Acetaminophen, Dexamethasone, Biopsy, FDG-PET, CT CAP, MRI, ECG, Echocardiogram
Biological · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 28, 2026, 4:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

NCT02073123
View directory record Official record
Conditions
Metastatic Melanoma, Stage III Melanoma, Stage IV Melanoma
Interventions
Indoximod, Ipilimumab, Nivolumab, Pembrolizumab
Drug
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Augusta, Georgia • Iowa City, Iowa • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 28, 2026, 4:02 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma

NCT01689974
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Ipilimumab, Radiation Therapy
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
19 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 28, 2026, 4:02 PM EDT
Recruiting Phase 2 Interventional

A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

NCT06594991
View directory record Official record
Conditions
Advanced Melanoma
Interventions
Fianlimab, Cemiplimab, Ipilimumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
12
States / cities
Los Angeles, California • Stanford, California • Hartford, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 28, 2026, 4:02 PM EDT
Terminated Phase 4 Interventional Results available

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

NCT01856023
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
High Dose Interleukin-2, Ipilimumab
Drug
Lead sponsor
Clinigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
12
States / cities
Tucson, Arizona • La Jolla, California • Miami Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 28, 2026, 4:02 PM EDT
Recruiting Phase 1 Interventional

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

NCT04248569
View directory record Official record
Conditions
Fibrolamellar Hepatocellular Carcinoma (FLC)
Interventions
DNAJB1-PRKACA peptide vaccine, Nivolumab, Ipilimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2034
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 28, 2026, 4:02 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer

NCT01471197
View directory record Official record
Conditions
Lung Cancer - Non Small Cell
Interventions
Ipilimumab, Pemetrexed
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Greenbrae, California • Galesburg, Illinois • Quincy, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 28, 2026, 4:02 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

NCT04396860
View directory record Official record
Conditions
Gliosarcoma, MGMT-Unmethylated Glioblastoma
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Ipilimumab, Nivolumab, NovoTTF-100A Device, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide
Procedure · Biological · Device + 3 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
285
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 210 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 28, 2026, 4:02 PM EDT
Completed Phase 2 Interventional

Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy

NCT02020070
View directory record Official record
Conditions
Metastatic Castration Sensitive Prostate Cancer
Interventions
Degarelix, Ipilimumab, Radical Prostatectomy
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 28, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer

NCT02872116
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
Interventions
Nivolumab, Ipilimumab, Oxaliplatin, Capecitabine, Leucovorin, Fluorouracil
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
2,031 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
27
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 28, 2026, 4:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

NCT03369223
View directory record Official record
Conditions
Advanced Cancer
Interventions
BMS-986249, Nivolumab, Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
19
States / cities
Aurora, Colorado • Denver, Colorado • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 28, 2026, 4:02 PM EDT
Recruiting Phase 2 Interventional

Axitinib and Nivolumab for the Treatment of Mucosal Melanoma

NCT05384496
View directory record Official record
Conditions
Mucosal Melanoma
Interventions
Nivolumab and/or Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), axitinib
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 28, 2026, 4:02 PM EDT
Terminated Phase 1 Interventional Results available

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02408861
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma, Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Unresectable Solid Neoplasm, HIV-associated Cancers
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 28, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney

NCT03138512
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
nivolumab, ipilimumab, nivolumab placebo, ipilimumab placebo
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
21
States / cities
Birmingham, Alabama • Springdale, Arkansas • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 28, 2026, 4:02 PM EDT
Completed Phase 2 Interventional

Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab

NCT03126331
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 28, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

NCT05005273
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab, Ipilimumab, BMS-986207, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
17
States / cities
Tucson, Arizona • Fountain Valley, California • Fort Myers, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 28, 2026, 4:02 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

NCT01696045
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 28, 2026, 4:02 PM EDT
Recruiting Phase 2 Interventional

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

NCT06712927
View directory record Official record
Conditions
Melanoma, Brain Metastases
Interventions
Ipilimumab, Nivolumab + Relatlimab FDC
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 28, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)

NCT03302234
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab, Ipilimumab, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
25
States / cities
Phoenix, Arizona • Burbank, California • Monterey, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 28, 2026, 4:02 PM EDT